OBJECTIVE: It is unclear why despite a comparable cardiometabolic risk profile, "metabolically benign" overweight/obese individuals show an elevated risk of cardiovascular disease compared to normal weight individuals. DESIGN AND METHODS: In cross-sectional analyses, we compared levels of ectopic fat (epicardial, pericardial, and hepatic fat) and adipokines (leptin, soluble leptin receptor, and high molecular weight [HMW] adiponectin) among metabolically benign (MBO) and at-risk overweight/obese (ARO), and metabolically benign normal weight (MBNW) women, screened for the Kronos Early Estrogen Prevention Study. We defined "metabolically benign" with ≤ 1, and "at-risk" with ≥2 components of the metabolic syndrome. RESULTS: Compared to MBO women, ARO women had significantly elevated odds of being in the top tertile of epicardial fat (OR: 1.76, 95% CI: 1.04-2.99), hepatic fat (OR: 1.90, 95% CI:1.12-3.24) and leptin (OR: 2.15, 95% CI: 1.23-3.76), and the bottom tertile of HMW-adiponectin (OR: 2.90, 95% CI: 1.62-5.19). Compared to MBNW women, MBO women had significantly higher odds of being in the top tertile of epicardial fat (OR: 5.17, 95% CI: 3.22-8.29), pericardial fat (OR: 9.27, 95% CI: 5.52-15.56) and hepatic fat (OR: 2.72, 95% CI: 1.77-4.19) and the bottom tertile of HMW adiponectin levels (OR: 2.51, 95% CI: 1.60-3.94). CONCLUSIONS: Levels of ectopic fat and the adverse adipokine profile increase on a continuum of BMI, suggesting that the metabolically benign phenotype may be a transient state.
RCT Entities:
OBJECTIVE: It is unclear why despite a comparable cardiometabolic risk profile, "metabolically benign" overweight/obese individuals show an elevated risk of cardiovascular disease compared to normal weight individuals. DESIGN AND METHODS: In cross-sectional analyses, we compared levels of ectopic fat (epicardial, pericardial, and hepatic fat) and adipokines (leptin, soluble leptin receptor, and high molecular weight [HMW] adiponectin) among metabolically benign (MBO) and at-risk overweight/obese (ARO), and metabolically benign normal weight (MBNW) women, screened for the Kronos Early Estrogen Prevention Study. We defined "metabolically benign" with ≤ 1, and "at-risk" with ≥2 components of the metabolic syndrome. RESULTS: Compared to MBO women, AROwomen had significantly elevated odds of being in the top tertile of epicardial fat (OR: 1.76, 95% CI: 1.04-2.99), hepatic fat (OR: 1.90, 95% CI:1.12-3.24) and leptin (OR: 2.15, 95% CI: 1.23-3.76), and the bottom tertile of HMW-adiponectin (OR: 2.90, 95% CI: 1.62-5.19). Compared to MBNW women, MBO women had significantly higher odds of being in the top tertile of epicardial fat (OR: 5.17, 95% CI: 3.22-8.29), pericardial fat (OR: 9.27, 95% CI: 5.52-15.56) and hepatic fat (OR: 2.72, 95% CI: 1.77-4.19) and the bottom tertile of HMW adiponectin levels (OR: 2.51, 95% CI: 1.60-3.94). CONCLUSIONS: Levels of ectopic fat and the adverse adipokine profile increase on a continuum of BMI, suggesting that the metabolically benign phenotype may be a transient state.
Authors: M Brochu; A Tchernof; I J Dionne; C K Sites; G H Eltabbakh; E A Sims; E T Poehlman Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Unab I Khan; Alexandra D Ogorodnikova; Linzhi Xu; Dan Wang; Sylvia Wassertheil-Smoller; Gloria Y F Ho; Mary Fran R Sowers; Swapnil N Rajpathak; Matthew A Allison; Rachel H Mackey; Mara Z Vitolins; Joann E Manson; Rachel P Wildman Journal: Obesity (Silver Spring) Date: 2013-12-20 Impact factor: 5.002
Authors: Gary Huang; Dan Wang; Irfan Zeb; Matthew J Budoff; S Mitchell Harman; Virginia Miller; Eliot A Brinton; Samar R El Khoudary; JoAnn E Manson; MaryFran R Sowers; Howard N Hodis; George R Merriam; Marcelle I Cedars; Hugh S Taylor; Frederick Naftolin; Rogerio A Lobo; Nanette Santoro; Rachel P Wildman Journal: Atherosclerosis Date: 2011-12-09 Impact factor: 5.162
Authors: Alexandra D Ogorodnikova; Mimi Kim; Aileen P McGinn; Paul Muntner; Unab Khan; Rachel P Wildman Journal: Obesity (Silver Spring) Date: 2011-07-28 Impact factor: 5.002
Authors: Kevin E Kip; Oscar C Marroquin; David E Kelley; B Delia Johnson; Sheryl F Kelsey; Leslee J Shaw; William J Rogers; Steven E Reis Journal: Circulation Date: 2004-02-17 Impact factor: 29.690
Authors: Jean L Chan; Susann Blüher; Nikos Yiannakouris; Marc A Suchard; Jurgen Kratzsch; Christos S Mantzoros Journal: Diabetes Date: 2002-07 Impact factor: 9.461
Authors: Virginia M Miller; Vesna D Garovic; Kent R Bailey; Brian D Lahr; Michelle M Mielke; Wendy M White; Muthuvel Jayachandran Journal: Atherosclerosis Date: 2016-09-09 Impact factor: 5.162
Authors: Virginia M Miller; Fredrick Naftolin; Sanjay Asthana; Dennis M Black; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; N Maritza Dowling; Carey E Gleason; Howard N Hodis; Muthuvel Jayachandran; Kejal Kantarci; Rogerio A Lobo; JoAnn E Manson; Lubna Pal; Nanette F Santoro; Hugh S Taylor; S Mitchell Harman Journal: Menopause Date: 2019-09 Impact factor: 2.953
Authors: Maude Perreault; Michael A Zulyniak; Flavia Badoud; Susan Stephenson; Alaa Badawi; Andrea Buchholz; David M Mutch Journal: PLoS One Date: 2014-02-10 Impact factor: 3.240